Norrin treatment preserves vision and retinal cells in diabetic rats, study finds

Treatment with the signalling molecule norrin prevented vision loss in diabetic rats, according to a study from the University of Michigan published in the journal Diabetes. The treatment also limited leakage from retinal blood vessels, inflammation and the death of retinal cells. The work points to a possible alternative to current therapies for diabetic retinopathy, which target a different pathway.

The problem with current treatments

Diabetic retinopathy arises when diabetes damages the blood vessels of the retina, the light-sensitive tissue at the back of the eye. Early disease may cause no symptoms or only mild ones, but poorly managed diabetes can eventually lead to blindness.

Existing drugs act against vascular endothelial growth factor (VEGF), a protein that drives the formation of new blood vessels and also makes vessels more permeable. In retinopathy, excess VEGF produces abnormal vessel growth and leakage, both of which impair vision. According to the research team, anti-VEGF therapy needs repeated injections and does not fully control the disease in half of treated patients.

What the rat study showed

The group, led by David Antonetti, a research professor of ophthalmology and visual sciences at the university's Kellogg Eye Center, had previously shown in cell studies that norrin can reverse the effects of VEGF on the barrier formed by blood vessel walls. The new study tested this in an animal model.

After rats developed diabetes, their norrin levels fell, and this coincided with reduced vision. Injecting the animals with norrin prevented the loss of vision. The treatment also reduced the loss of nerve cells involved in sight, and it prevented retinal cell death and inflammation at both early and late stages of diabetes.

Notably, starting norrin after vision had already declined stopped further loss. This suggests that the molecule may have a role in intervention as well as prevention, although the source does not report whether lost vision was recovered.

Mechanisms and clinical links

The researchers identified several genes whose activity changed with norrin treatment. They are now investigating how these genes contribute to restoring the vascular barrier, which should help clarify how the molecule acts in the retina.

The laboratory's earlier work has also fed into drug development. It helped EyeBio and Merck design clinical trials of drugs that increase the activity of cell receptors responding to norrin. Antonetti additionally contributed to Merck's development of a drug for macular edema in adults, a major cause of vision loss in diabetic retinopathy. If that drug succeeds, it would be the first new therapy for the condition in 16 years.

Limitations and next steps

The findings come from diabetic rats, and the source does not give group sizes, dosing details or how long the protective effects lasted. Results in animal models do not always carry over to patients, and delivering norrin to the human retina would raise practical questions of its own. The study itself does not test norrin in people.

The next steps described are mechanistic: working out which genes mediate barrier restoration and how they interact. Those results, together with the ongoing trials of drugs that act on norrin-responsive receptors, will help show whether targeting this pathway can complement or improve on anti-VEGF treatment.

The study is by Laura González-González and colleagues, titled "Norrin Treatment Prevents Vascular Permeability and Neural Cell Loss While Preserving Vision in Diabetic Rats" (Diabetes, 2026, DOI: 10.2337/db26-0340).

Source: Treatment with norrin helps maintain healthy blood vessels and preserve vision in diabetic rats (Medical Xpress, 31 October 2026).

Image: AI-generated illustration.